Evidence map›Paper›PMID 25484089›Full record

ArticleAutophagy2015

Mutations in the ubiquitin-binding domain of OPTN/optineurin interfere with autophagy-mediated degradation of misfolded proteins by a dominant-negative mechanism.

Wen-Chuan Shen, Huei-Ying Li, Guang-Chao Chen, Yijuang Chern, Pang-Hsien Tu

Open access · bronzeAbstract read
In one paragraph

Article in Autophagy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 2 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 2 syntheses or guidelines pooled it, 166 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Heavy metal-induced disruption of the autophagy-lysosomal pathway: implications for aging and neurodegenerative disorders.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Wen-Chuan Shena Taiwan International Graduate Program in Molecular Medicine; National Yang-Ming University and Academia Sinica ; Taipei , Taiwan.
Huei-Ying Li
Guang-Chao Chen
Yijuang Chern
Pang-Hsien Tu
Academia Sinica · TWInstitute of Biological Chemistry, Academia Sinica · TWInstitute of Biomedical Science · GBInstitute of Biomedical Sciences, Academia Sinica · TWInstitute of Molecular Biology, Academia Sinica · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OPTN (optineurin) is an autophagy receptor and mutations in the OPTN gene result in familial glaucoma (E50K) and amyotrophic lateral sclerosis (ALS) (E478G). However, the mechanisms through which mutant OPTN leads to human diseases remain to be characterized. Here, we demonstrated that OPTN colocalized with inclusion bodies (IBs) formed by mutant HTT/huntingtin protein (mHTT) in R6/2 transgenic mice and IBs formed by 81QNmHTT (nuclear form), 109QmHTT (cytoplasmic form) or the truncated form of TARDBP/TDP-43 (TARDBP(ND251)) in Neuro2A cells. This colocalization required the ubiquitin (Ub)-binding domain (UbBD, amino acids 424 to 511) of OPTN. Overexpression of wild-type (WT) OPTN decreased IBs through K63-linked polyubiquitin-mediated autophagy. E50K or 210 to 410Δ (with amino acids 210 to 410 deleted) whose mutation or deletion was outside the UbBD decreased the IBs formed by 109QmHTT or TARDBP(ND251), as was the case with WT OPTN. In contrast, UbBD mutants, including E478G, D474N, UbBDΔ, 411 to 520Δ and 210 to 520Δ, increased accumulation of IBs. UbBD mutants (E478G, UbBDΔ) retained a substantial ability to interact with WT OPTN, and were found to colocalize with polyubiquitinated IBs, which might occur indirectly through their WT partner in a WT-mutant complex. They decreased autophagic flux evidenced by alteration in LC3 level and turnover and in the number of LC3-positive puncta under stresses like starvation or formation of IBs. UbBD mutants exhibited a weakened interaction with MYO6 (myosin VI) and TOM1 (target of myb1 homolog [chicken]), important for autophagosome maturation, in cells or sorted 109QmHtt IBs. Taken together, our data indicated that UbBD mutants acted as dominant-negative traps through the formation of WT-mutant hybrid complexes to compromise the maturation of autophagosomes, which in turn interfered with OPTN-mediated autophagy and clearance of IBs.

Indexed as

Amyotrophic Lateral SclerosisAnimalsAutophagyBinding SitesCell Cycle ProteinsCytoplasmDNA-Binding ProteinsEye ProteinsHumansMembrane Transport ProteinsMiceMutant ProteinsMutationProtein BindingProtein FoldingTranscription Factor TFIIIACell Cycle ProteinsDNA-Binding ProteinsEye ProteinsMembrane Transport ProteinsMutant ProteinsOPTN protein, humanOptn protein, mouseTranscription Factor TFIIIAAb, antibodyALS, amyotrophic lateral sclerosisautophagyBafA1, bafilomycin A1CCD, coiled-coil domaindominant-negativeEf, FRET efficiencyFT, filter-trap assayHD, Huntington diseasehuntingtinIBs, inclusion bodiesIP, immunoprecipitationK48, lysine 48K63, lysine 63LIR, LC3-interacting regionmHTT, mutant huntingtinMYO6, myosin VIoptineurinOPTN, optineurinPBS, phosphate-buffered salinePFA, paraformaldehydeTARDBP/TDP-43TARDBP/TDP-43, TAR DNA-binding proteinTBK1, TANK-binding kinase 1TUBA, alpha tubulinUbBD, ubiquitin-binding domainUb, ubiquitin B/C/DUPS, ubiquitin-proteasome systemWB, western blotWT, wild type

Identifiers

PMID25484089
PMCPMC4502753
OpenAlexW2019986404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.